超百种肺癌创新药亮相世界肺癌大会，中国创新药崭露头角

Core Insights - The 2025 World Lung Cancer Congress held in Barcelona showcased over a hundred innovative drugs, highlighting the increasing international recognition of Chinese innovative drugs [1] - Lung cancer remains a leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for 80%-85% of cases, and significant advancements in targeted and immunotherapy drugs have been made [2] - The conference featured significant clinical trial results, including AstraZeneca's positive findings on osimertinib combined with chemotherapy, demonstrating a median overall survival of nearly four years for patients with specific EGFR mutations [2] - The ADC I-DXd, targeting B7-H3, showed promising results in a phase II trial for small cell lung cancer, with an objective response rate of 48.2% and a disease control rate of 87.6% [3] - Chinese pharmaceutical companies made notable strides, with 35 oral presentations at the conference, including groundbreaking research from Bai Li Tian Heng on the dual-targeting ADC, iza-bren, achieving a 100% objective response rate [4][5] Industry Developments - The global lung cancer drug research landscape is evolving, with targeted therapies and immunotherapies gaining traction, marking a golden era for lung cancer treatment [2] - The ADC I-DXd is the first of its kind targeting B7-H3 and is currently in phase III trials, which could significantly impact the development of B7-H3 targeted drugs [3] - Bai Li Tian Heng's iza-bren has been recognized for its innovative approach, with its clinical data being highlighted at the congress, indicating a strong validation of Chinese innovation capabilities [4][5] - The approval of Shuwotein, a novel oral targeted drug for EGFR Exon20ins NSCLC, marks a significant milestone as it is the only drug approved for this mutation globally [6] - QLC5508, another ADC targeting B7-H3, has shown promising results in early trials, indicating a growing focus on innovative therapies for small cell lung cancer [7] - The increasing competitiveness of Chinese innovative drugs in clinical data and progress is leading to a trend of these drugs entering international markets [7]